Dr. Heather Ann Wakelee, MD

Dr. Wakelee practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Wakelee's NPI, 1720137094, was assigned on January 9, 2007. Dr. Wakelee graduated from The Johns Hopkins University School of Medicine in 1996. Dr. Wakelee holds California license A63195.

Dr. Wakelee's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Wakelee's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Wakelee to 1 more hospital, named with a free account. Dr. Wakelee's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wakelee practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Wakelee's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Wakelee is board certified in medical oncology by the American Board of Internal Medicine. Dr. Wakelee is licensed in California.

Dmand AI lists lung cancer and multiple myeloma among the conditions Dr. Wakelee treats.

CMS data shows 554 Medicare services from Dr. Wakelee across 4 procedure codes in 2024, for 103 Medicare patients. Medicare paid $44,025 for them.

CMS counts 103 Medicare patients who saw Dr. Wakelee in 2024. The largest group is 65 to 74, with 45 patients. 75% of them have cancer, and 64% have high cholesterol. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wakelee's median patient age at 66, with 61% women.

In 2024, Dr. Wakelee wrote 78 Medicare Part D claims for 18 patients. 35% of them were for generic drugs. CMS names the drug for 32 of them, across 1 drug with 11 or more claims each, at $625,194 in total drug cost. In 2023, CMS named 38 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Wakelee for performance year 2024, reported as part of a group. Dr. Wakelee accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wakelee as offering telehealth.

Dmand AI links 368 papers to Dr. Wakelee, published from 2009 to 2025. 2017 was the busiest year, with 32. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and ErbB Receptors. Dr. Wakelee has published most often in J Thorac Oncol. Dr. Wakelee's most frequent co-authors are Joel William Neal, MD, PhD, Maximilian Diehn, MD, PhD and Millie Snigdha Das, MD.

Dmand AI links Dr. Wakelee to 20 clinical trials, 7 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. Stanford University sponsors the most, 7.

CMS Open Payments shows 106 general payments to Dr. Wakelee from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 54% of the total. Genentech, Inc. paid the most, $37,074. It also lists 16 research payments totaling $19,392 from 2016 to 2025.

Dmand AI lists 1 award for Dr. Wakelee, most recently CMS Stage 1 EHR in 2013.

Dr. Wakelee graduated from The Johns Hopkins University School of Medicine in 1996. Dr. Wakelee is a member of ASCO, European Society of Medical Oncology (ESMO) and International Association for the Study of Lung Cancer (IASLC).

Dr. Wakelee is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.